Quince Therapeutics
QNCX
41 hedge funds and large institutions have $19.2M invested in Quince Therapeutics in 2025 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 4 closing their positions.
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
54% more capital invested
Capital invested by funds: $12.5M → $19.2M (+$6.72M)
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
11% more funds holding
Funds holding: 37 → 41 (+4)
5.29% more ownership
Funds ownership: 16.67% → 21.95% (+5.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.12M |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$1.05M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$908K |
| 4 |
IC
IEQ Capital
Foster City,
California
|
+$902K |
| 5 |
AC
Almitas Capital
Santa Monica,
California
|
+$824K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Rockefeller Capital Management
New York
|
-$280K |
| 2 |
IP
Intellectus Partners
San Francisco,
California
|
-$88K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$61.6K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$55.6K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$37.4K |
QNCX Hedge Fund Activity: Q3 2025 in Review
41 of the 7,645 institutional investors tracked by Wall St. Rank reported a position in Quince Therapeutics (QNCX) for Q3 2025, worth a combined $19.2M — up 54% from $12.5M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new QNCX positions and 4 closed out — a net gain of 4 holders — while 12 added to existing stakes and 8 trimmed.
The largest buyer was Millennium Management, adding an estimated $2.12M. The largest seller was Rockefeller Capital Management, exiting entirely with an estimated $280K sold.
- 41 institutional investors held Quince Therapeutics (QNCX) as of Q3 2025, up from 37 in Q2 2025.
- Funds reported $19.2M of Quince Therapeutics stock for Q3 2025, up 54% quarter-over-quarter.
- 8 funds opened new Quince Therapeutics positions in Q3 2025 and 4 closed out, a net change of +4 holders.
- The largest Quince Therapeutics buyer in Q3 2025 was Millennium Management, an estimated $2.12M added.
- The largest Quince Therapeutics seller in Q3 2025 was Rockefeller Capital Management, an estimated $280K sold.
Based on aggregated 13F filings for Q3 2025.